Agenus Inc.
(NASDAQ:AGEN) reported updated three-year Phase 1b data showing durable survival with its botensilimab plus balstilimab combination in patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases.
Separately, the biotechnology company announced a private placement that could generate up to $340 million to fund its strategic focus on advancing the combination into Phase 3 testing in earlier-stage colon cancer.
Read Also: Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update Three-Year Data Show Durable Survival Benefit The latest results included 123 heavily pretreated patients.
With extended follow-up, the combination produced a median overall survival of 21.2 months, while the 24-month and 36-month overall survival rates reached 41% and 33%, respectively.
